.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a mean follow-up of 11 months, individuals with metastatic intestinal tumors that acquired biomarker-matched therapies based upon spreading lump DNA profiling revealed a higher professional advantage than those receiving incomparable treatment.